Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPM1002 vs BCG in HIV-unexposed Newborns
NCT01479972Phase 2Completed
- Sponsor
- Serum Life Sciences
- Start
- Nov 2011
- Primary completion
- Nov 2012
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of VPM1002 in Tuberculosis (TB) (2 arms), sponsored by Serum Life Sciences. Primary endpoint: Safety at 6 months. Started Nov 2011; status: completed.
02
Drugs
VPM1002
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01479972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01479972.